中华泌尿外科杂志
中華泌尿外科雜誌
중화비뇨외과잡지
CHINESE JOURNAL OF UROLOGY
2012年
2期
117-119
,共3页
李青%李明川%姜永光%刘俊敏
李青%李明川%薑永光%劉俊敏
리청%리명천%강영광%류준민
前列腺增生%下尿路症状%坦索罗辛%治疗剂量
前列腺增生%下尿路癥狀%坦索囉辛%治療劑量
전렬선증생%하뇨로증상%탄색라신%치료제량
Prostatic hyperplasia%Lower urinary tract symptoms%Tamsulosin%Therapeutic dose
目的 观察大剂量坦索罗辛治疗BPH引起LUTS的临床效果.方法 采用前瞻性、随机对照研究,观察期为4周.261例经诊断为BPH引起LUTS的患者简单随机分为两组,分别采用口服坦索罗辛0.2 mg每晚1次(126例)或0.4 mg每晚1次(135例),比较治疗前后的IPSS评分和Qmax. 结果 0.2 mg组IPSS由治疗前的17.72±2.50降至10.21±1.95,平均下降7.59±2.74；Qmax由(8.78±3.70) ml/s升至(12.74±2.99) ml/s,平均上升(4.31±3.01) ml/s；治疗前后比较差异均有统计学意义(P＜0.05).0.4 mg组IPSS由治疗前的19.24±3.22降至11.21±3.02,平均下降8.49±3.73；Qmax由(7.74±1.97) ml/s升至(12.04±2.46) ml/s,平均上升(4.73±2.97) ml/s；治疗前后比较差异均有统计学意义(P＜0.05).两组IPSS评分变化差异无统计学意义(P＞0.05),Qmax变化差异有统计学意义(P＜0.05).将两组患者按体质量≤55.0、55.1～ 65.0、65.1～75.0、＞75.0 kg进一步分组,发现体质量65.1 ～75.0、＞75.0 kg两组间IPSS和Qmax变化情况比较差异均有统计学意义(P＜0.05).两组间的不良反应发生率差异无统计学意义(P＞0.05). 结论 对于体质量≤65.0 kg的患者而言,使用大剂量坦索罗辛对于改善BPH引起的LUTS并不能带来显著益处,但对于体质量≥65.1 kg患者可建议增加坦索罗辛的剂量.
目的 觀察大劑量坦索囉辛治療BPH引起LUTS的臨床效果.方法 採用前瞻性、隨機對照研究,觀察期為4週.261例經診斷為BPH引起LUTS的患者簡單隨機分為兩組,分彆採用口服坦索囉辛0.2 mg每晚1次(126例)或0.4 mg每晚1次(135例),比較治療前後的IPSS評分和Qmax. 結果 0.2 mg組IPSS由治療前的17.72±2.50降至10.21±1.95,平均下降7.59±2.74；Qmax由(8.78±3.70) ml/s升至(12.74±2.99) ml/s,平均上升(4.31±3.01) ml/s；治療前後比較差異均有統計學意義(P＜0.05).0.4 mg組IPSS由治療前的19.24±3.22降至11.21±3.02,平均下降8.49±3.73；Qmax由(7.74±1.97) ml/s升至(12.04±2.46) ml/s,平均上升(4.73±2.97) ml/s；治療前後比較差異均有統計學意義(P＜0.05).兩組IPSS評分變化差異無統計學意義(P＞0.05),Qmax變化差異有統計學意義(P＜0.05).將兩組患者按體質量≤55.0、55.1～ 65.0、65.1～75.0、＞75.0 kg進一步分組,髮現體質量65.1 ～75.0、＞75.0 kg兩組間IPSS和Qmax變化情況比較差異均有統計學意義(P＜0.05).兩組間的不良反應髮生率差異無統計學意義(P＞0.05). 結論 對于體質量≤65.0 kg的患者而言,使用大劑量坦索囉辛對于改善BPH引起的LUTS併不能帶來顯著益處,但對于體質量≥65.1 kg患者可建議增加坦索囉辛的劑量.
목적 관찰대제량탄색라신치료BPH인기LUTS적림상효과.방법 채용전첨성、수궤대조연구,관찰기위4주.261례경진단위BPH인기LUTS적환자간단수궤분위량조,분별채용구복탄색라신0.2 mg매만1차(126례)혹0.4 mg매만1차(135례),비교치료전후적IPSS평분화Qmax. 결과 0.2 mg조IPSS유치료전적17.72±2.50강지10.21±1.95,평균하강7.59±2.74；Qmax유(8.78±3.70) ml/s승지(12.74±2.99) ml/s,평균상승(4.31±3.01) ml/s；치료전후비교차이균유통계학의의(P＜0.05).0.4 mg조IPSS유치료전적19.24±3.22강지11.21±3.02,평균하강8.49±3.73；Qmax유(7.74±1.97) ml/s승지(12.04±2.46) ml/s,평균상승(4.73±2.97) ml/s；치료전후비교차이균유통계학의의(P＜0.05).량조IPSS평분변화차이무통계학의의(P＞0.05),Qmax변화차이유통계학의의(P＜0.05).장량조환자안체질량≤55.0、55.1～ 65.0、65.1～75.0、＞75.0 kg진일보분조,발현체질량65.1 ～75.0、＞75.0 kg량조간IPSS화Qmax변화정황비교차이균유통계학의의(P＜0.05).량조간적불량반응발생솔차이무통계학의의(P＞0.05). 결론 대우체질량≤65.0 kg적환자이언,사용대제량탄색라신대우개선BPH인기적LUTS병불능대래현저익처,단대우체질량≥65.1 kg환자가건의증가탄색라신적제량.
Objective To evaluate the effect of increasing doses of tamsulosin in lower urinary tract symptom (LUTS) of benign prostatic hyperplasia (BPH). Methods A prospective self-controlled clinical trail was performed.Two hundred and sixty-one patients who had LUTS of BPH were enrolled in this prospective 4 weeks study of tamsulosin.The patients were randomly divided into 2 groups:took tamsulosin 0.2 mg QN (n =126,group A) and 0.4 mg QN (n =135,group B) respectively.The IPSS score and maximum flow rate before and after treatment were compared between the 2 groups. Results The IPSS score of group A decreased from 17.72 ± 2.50 to 10.21 ± 1.95,average decreased 7.59 ± 2.74 ； maximum flow rate was elevated from (8.78 ± 3.70) ml/s to ( 12.74 ± 2.99 ) ml/s,average increased (4.31 ± 3.01 )ml/s.The IPSS score of group B decreased from 19.24 ± 3.22 to 11.21 ± 3.02,average decreased 8.49 ±3.73； maximum flow rate was elevated from (7.74 ± 1.97) ml/s to ( 12.04 ± 2.46) ml/s,average increased (4.73 ± 2.97) ml/s.There was no significant difference of the changes of IPSS score between the 2 groups ( P ＞ 0.05 ),but there was a significant difference of the changes of maximum flow rate between the 2 groups ( P ＜ 0.05 ).The results was further analyzed by sub grouped ( by patient body weight,divided into ≤55.0 kg,55.1 -65.0 kg,65.1 -75.0 kg,＞75.0 kg group).There were significant differences of the changes of IPSS score and maximum flow rate between the 2 groups in 65.1 - 75.0 kg and ＞ 75.0 kg subgroups ( P ＜ 0.05 ).The incidence of side effects between the 2 groups was not significantly different (P ＞ 0.05). Conclusions For most patients,the use of high-dose tamsulosin in improving LUTS caused by BPH can not bring significant benefits.But if the patient's weight is more than 65.0 kg,increasing the dose of tamsulosin is suggested for consideration.
